Table 2 Safety of blinatumomab induction therapy
All grades | Grades 1–2* | Grades 3–4* | |
|---|---|---|---|
Fever | 9 (36%) | 9 (36%) | 0 |
Anaemia | 6 (24%) | 4 (16%) | 2 (8%) |
Lymphocyte count decrease | 6 (24%) | 2 (8%) | 4 (16%) |
Hyperglycaemia | 6 (24%) | 5 (20%) | 1 (4%) |
White blood cell count decrease | 4 (16%) | 3 (12%) | 1 (4%) |
Platelet count decrease | 4 (16%) | 3 (12%) | 1 (4%) |
Hypoalbuminaemia | 4 (16%) | 3 (12%) | 1 (4%) |
Cytokine release syndrome | 4 (16%) | 4 (16%) | 0 |
Dyspnea | 4 (16%) | 4 (16%) | 0 |
Limb oedema | 4 (16%) | 4 (16%) | 0 |
Headache | 4 (16%) | 4 (16%) | 0 |
Hypomagnesaemia | 4 (16%) | 4 (16%) | 0 |
Neutrophil count decrease | 3 (12%) | 2 (8%) | 1 (4%) |
Diarrhoea | 3 (12%) | 3 (12%) | 0 |
GGT level elevation | 2 (8%) | 0 | 2 (8%) |
Sepsis | 2 (8%) | 0 | 2 (8%) |
Alkaline phosphatase level elevation | 2 (8%) | 1 (4%) | 1 (4%) |
Tremors | 2 (8%) | 2 (8%) | 0 |
Constipation | 2 (8%) | 2 (8%) | 0 |
Paresthesia | 2 (8%) | 2 (8%) | 0 |
Hyperkalaemia | 2 (8%) | 2 (8%) | 0 |
Hypocalcaemia | 2 (8%) | 2 (8%) | 0 |
Hypokalaemia | 2 (8%) | 2 (8%) | 0 |
Hyponatraemia | 2 (8%) | 2 (8%) | 0 |
Immune system disorders - Others: hypogammaglobulinaemia | 2 (8%) | 2 (8%) | 0 |
Confusion | 1 (4%) | 0 | 1 (4%) |
Encephalopathy | 1 (4%) | 0 | 1 (4%) |
Anxiety | 1 (4%) | 0 | 1 (4%) |
Fatigue | 1 (4%) | 0 | 1 (4%) |
Ileal perforation | 1 (4%) | 0 | 1 (4%) |
Musculoskeletal and connective tissue disorder - Others: hip pain | 1 (4%) | 0 | 1 (4%) |
Thromboembolic event | 1 (4%) | 0 | 1 (4%) |
Catheter-related infections | 1 (4%) | 0 | 1 (4%) |
Cholecystitis | 1 (4%) | 0 | 1 (4%) |
